BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23732297)

  • 1. Drug-drug interactions and metabolism in cytochrome P450 2C knockout mice: application to troleandomycin and midazolam.
    Grimsley A; Gallagher R; Hutchison M; Pickup K; Wilson ID; Samuelsson K
    Biochem Pharmacol; 2013 Aug; 86(4):529-38. PubMed ID: 23732297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
    Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
    Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and simultaneous measurement of midazolam, 1'-hydroxymidazolam and digoxin by liquid chromatography/tandem mass spectrometry: application to an in vivo study to simultaneously measure P-glycoprotein and cytochrome P450 3A activity.
    Xue X; Huang M; Xiao H; Qin X; Huang L; Zhong G; Bi H
    J Pharm Biomed Anal; 2011 Apr; 55(1):187-93. PubMed ID: 21316177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression.
    Perloff MD; Von Moltke LL; Greenblatt DJ
    Xenobiotica; 2003 Apr; 33(4):365-77. PubMed ID: 12745872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
    Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes.
    Warrington JS; Poku JW; von Moltke LL; Shader RI; Harmatz JS; Greenblatt DJ
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1024-31. PubMed ID: 10688619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
    Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
    Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes.
    van Waterschoot RA; van Herwaarden AE; Lagas JS; Sparidans RW; Wagenaar E; van der Kruijssen CM; Goldstein JA; Zeldin DC; Beijnen JH; Schinkel AH
    Mol Pharmacol; 2008 Mar; 73(3):1029-36. PubMed ID: 18156313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.
    Zhang X; Quinney SK; Gorski JC; Jones DR; Hall SD
    Drug Metab Dispos; 2009 Aug; 37(8):1587-97. PubMed ID: 19420129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver.
    Hasegawa M; Tahara H; Inoue R; Kakuni M; Tateno C; Ushiki J
    Drug Metab Dispos; 2012 Mar; 40(3):474-80. PubMed ID: 22126990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam.
    Kuze J; Mutoh T; Takenaka T; Oda N; Hanioka N; Narimatsu S
    Xenobiotica; 2013 Jul; 43(7):598-606. PubMed ID: 23282066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo inhibition of CYP3A-mediated midazolam metabolism by anchusan in rats.
    Saito Y; Nishimura Y; Kurata N; Iwase M; Aoki K; Yasuhara H
    J Pharmacol Sci; 2011; 115(3):399-407. PubMed ID: 21358120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
    Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
    Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam.
    Yang J; Atkins WM; Isoherranen N; Paine MF; Thummel KE
    Clin Pharmacol Ther; 2012 Mar; 91(3):442-9. PubMed ID: 22048224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans.
    Klieber S; Hugla S; Ngo R; Arabeyre-Fabre C; Meunier V; Sadoun F; Fedeli O; Rival M; Bourrie M; Guillou F; Maurel P; Fabre G
    Drug Metab Dispos; 2008 May; 36(5):851-62. PubMed ID: 18256203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Green tea extract affects the cytochrome P450 3A activity and pharmacokinetics of simvastatin in rats.
    Misaka S; Kawabe K; Onoue S; Werba JP; Giroli M; Watanabe H; Yamada S
    Drug Metab Pharmacokinet; 2013; 28(6):514-8. PubMed ID: 23698259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of R667, a novel emphysema agent, on the pharmacokinetics of midazolam in healthy men.
    Brennan BJ; Brown AB; Kolis SJ; Rutman O; Gooden C; Davies BE
    J Clin Pharmacol; 2006 Feb; 46(2):222-8. PubMed ID: 16432274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
    Polasek TM; Miners JO
    Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.